Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

HTG Molecular Diagnostics and PROOF Centre Partner to Commercialize COPD Prognostic Test

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
The license agreement provides HTG Molecular Diagnostics exclusive rights to commercialize PROOF Centre-developed gene expression blood tests for the prognosis of COPD patients who will experience frequent exacerbations.

HTG Molecular Diagnostics will develop the assay on its proprietary qNPA platform. The PROOF Centre -- a not-for-profit organization focused on developing blood tests for chronic organ disease -- will be involved in the clinical validation in Canada, and provide key opinion leader support for regulatory approval in North America.

Lung attacks are the leading cause of emergency room visits and hospitalizations among chronic disease sufferers, accounting for over $5.7 billion direct, and $6.7 billion indirect healthcare costs every year in Canada alone. According to the World Health Organization (WHO), an estimated 210 million people worldwide have COPD and three million deaths are attributed to the disease annually. WHO predicts COPD will become the third leading cause of death by 2030. A large portion of COPD-related mortality is due to lung attacks.

"The development of these blood tests has been driven by a huge unmet clinical and social need," says Dr. Bruce McManus, Director of the PROOF Centre. "This agreement with HTG Molecular Diagnostics will facilitate bringing these tests to market faster, providing physicians with tools to improve patient care and management and help alleviate suffering of patients with COPD."

Currently, physicians have limited capabilities to predict which COPD patients will suffer frequent lung attacks, episodes that result in hospitalization and a reduced quality of life. The ability to identify these patients earlier will enable physicians to intervene sooner and better tailor treatment for the individual patient to prevent future lung attacks.

TJ Johnson, CEO of HTG Molecular Diagnostics, states, "Delivery of an accurate, early predictor of frequent patient lung attacks, and providing the ability to personalize preventive care is of paramount importance to pulmonology practitioners and patients. This agreement is the first of many that HTG Molecular Diagnostics and PROOF Centre hope to have to bring medically valuable biomarker tests to the clinic."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

HTG Molecular Diagnostics Licenses Breast Cancer Marker Patent Portfolio From Merck
Company has been granted a non-exclusive license to develop, manufacture, and commercialize breast cancer diagnostic tests under Merck's patent portfolio.
Wednesday, July 11, 2012
HTG Molecular Diagnostics Appoints Debra Gordon to Vice President, Chief Legal Counsel
Debra Gordon brings diverse legal experience as a business transactional and intellectual property attorney at leading U.S. and international law firms.
Tuesday, June 21, 2011
HTG Molecular Diagnostics Secures New Investor, SR One
Venture capital arm of GlaxoSmithKline joins second tranche of series D financing round.
Wednesday, June 15, 2011
Scientific News
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Diagnosing Tumors of Unknown Origin
EPICUP® test is a tool that helps to identify up to 87% of cancers of unknown origin (COD).
New Possibilities Tumor Research
Grazer researchers say gene activity of the tumor from the analysis of circulating DNA in blood ahead.
Parkinson’s Test Could Aid Early Detection
A test that can detect Parkinson’s disease in the early stages of the illness has moved a step closer.
Linkage Biosciences Awarded NHS Contract
Comapny announces that it has been awarded a four-year contract by NHS Blood and Transplant (NHSBT) in the UK for implementation of the LinkSeq™ Real-Time PCR HLA typing product.
Diagnosing Bacterial Infections in Blood Samples
Researchers have diagnosed a bacterial infection from a blood sample in infants.
Neurodvelopmental Disorder Cause Linked to SON Gene
A genetic link has been discovered for a previously unxplained neurodevelopmental disorder.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Misdiagnosis in HCM Tests
Genetic tests for potentially fatal heart anomaly can misdiagnose condition in black Americans.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!